# TGFA

## Overview
Transforming growth factor alpha (TGFA) is a gene that encodes a transmembrane protein known as transforming growth factor alpha (TGF-α), which plays a pivotal role in cellular communication and growth regulation. TGF-α is a member of the epidermal growth factor (EGF) family and functions primarily as a ligand for the epidermal growth factor receptor (EGFR), initiating signaling pathways that influence cell proliferation, differentiation, and survival (Derynck1986Transforming; Brachmann1989Transmembrane). The protein is synthesized as a larger precursor that undergoes proteolytic cleavage to release the active peptide, which is involved in various physiological processes, including tissue repair and development. TGF-α's interaction with EGFR is crucial in both normal cellular functions and pathological conditions, such as cancer, where it can contribute to tumor growth and metastasis (Degl’Innocenti2010Integrated; Markowitz1990Growth). Additionally, genetic variations in TGFA have been linked to congenital anomalies like nonsyndromic cleft lip and palate, highlighting its significance in developmental biology (Lu2013TGFA).

## Structure
Transforming growth factor alpha (TGF-α) is a 50-amino-acid peptide that is initially synthesized as a larger precursor protein. This precursor includes a transmembrane region characterized by a hydrophobic domain flanked by basic amino acids. The precursor is cleaved by a specific protease to release the active TGF-α peptide, while the C-terminal portion remains on the cytoplasmic side and may play a role in signal transduction (Derynck1986Transforming).

The primary structure of TGF-α shares significant homology with epidermal growth factor (EGF), particularly in the sequence and positioning of cysteine residues, which are crucial for forming disulfide bonds that stabilize the protein's tertiary structure (Derynck1986Transforming). The secondary structure of TGF-α includes a short two-strand β-sheet and a disulfide bond, with a type II β-turn connecting the N- and C-terminal domain β-sheets (Groenen1994StructureFunction).

TGF-α is structurally constrained by disulfide bridges, which are essential for maintaining its biological activity. Mutations that disrupt these disulfide bonds result in loss of function, highlighting their importance in the protein's structure (DefeoJones1988StructureFunction). The flexibility of TGF-α, as indicated by its higher hydrogen-deuterium exchange rate, suggests a more dynamic structure compared to EGF (Prestrelski1992Solution).

## Function
Transforming growth factor alpha (TGFA) is a crucial protein involved in various cellular processes, primarily through its interaction with the epidermal growth factor receptor (EGFR). TGFA functions as a ligand for EGFR, triggering signaling pathways that regulate cell proliferation, differentiation, and survival. This interaction is essential for maintaining normal cellular functions and tissue homeostasis (Gottlieb1988Detection; Markowitz1990Growth).

In the human colon, TGFA is expressed in both normal and adenomatous epithelium, where it acts as a paracrine or autocrine growth factor. It stimulates epithelial proliferation by binding to EGFR, which is coexpressed in these tissues. This mechanism is vital for normal epithelial cell growth and repair, although it does not lead to malignant transformation (Markowitz1990Growth).

TGFA is also present in the gastrointestinal tract, where it is involved in cellular differentiation. It is localized to specific areas such as the luminal surface of the stomach and the villous epithelium of the small intestine, suggesting a role in maintaining the differentiated state of cells (Thomas1992Immunoreactivity). In the bone marrow, TGFA is found in erythroblasts and eosinophilic precursor cells, indicating its role in erythroid development and potential influence on hematopoietic cell growth (Walz1995Transforming).

## Clinical Significance
Mutations and alterations in the expression of the TGFA gene have been associated with several clinical conditions, particularly nonsyndromic oral clefts and certain cancers. TGFA has been implicated in the etiology of nonsyndromic cleft lip with or without cleft palate (NSCL/P), a common congenital anomaly. Studies have shown significant associations between specific single nucleotide polymorphisms (SNPs) in the TGFA gene and increased risk of NSCL/P, suggesting that genetic variations in TGFA contribute to craniofacial development issues (Machida1999Transforming; Lu2013TGFA). The gene's role in oral clefts is supported by evidence of its expression in the medial edge epithelium during palatal shelf fusion, although its exact mechanism remains unclear (Vieira2006Association).

TGFA has also been studied in relation to various cancers, including cutaneous malignant melanoma, breast cancer, and oral cancer, though its role in these conditions is not fully understood (Vieira2006Association). Alterations in TGFA expression levels have been observed in patients with nonsyndromic clefts, with lower expression noted in affected individuals compared to controls, indicating its potential involvement in the onset of these conditions (Rullo2007TGF).

## Interactions
Transforming growth factor alpha (TGFA) interacts with the epidermal growth factor receptor (EGFR), a critical interaction that promotes cell proliferation and metastasis in various cancers. The binding of TGFA to EGFR induces receptor autophosphorylation, activating downstream signaling pathways such as MEK/ERK and PI3K/AKT, which are involved in cell growth and survival (Degl’Innocenti2010Integrated; Brachmann1989Transmembrane). In colon cancer, TGFA is essential for the migratory and metastatic capabilities of cancer cells, particularly through its interaction with EGFR. Blocking EGFR with Cetuximab reduces cell migration and metastasis, highlighting the importance of this interaction (Mishra2019The).

TGFA is also involved in a positive regulatory loop with GLI1, where GLI1 enhances TGFA mRNA levels, and TGFA, in turn, enhances GLI1 activity. This loop promotes pro-metastatic states in colon cancer cells (Mishra2019The). In papillary thyroid carcinomas, the TGFA/EGFR signaling loop is associated with aggressive disease progression, particularly in cases with BRAF and RET/PTC mutations (Degl’Innocenti2010Integrated). The transmembrane form of TGFA can also activate EGFR through cell-cell contact, suggesting a role in intercellular signaling (Brachmann1989Transmembrane).


## References


[1. (Degl’Innocenti2010Integrated) Debora Degl’Innocenti, Chiara Alberti, Giancarlo Castellano, Angela Greco, Claudia Miranda, Marco A. Pierotti, Ettore Seregni, Maria Grazia Borrello, Silvana Canevari, and Antonella Tomassetti. Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active tgfa/egfr signaling loop in papillary thyroid carcinomas. PLoS ONE, 5(9):e12701, September 2010. URL: http://dx.doi.org/10.1371/journal.pone.0012701, doi:10.1371/journal.pone.0012701. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0012701)

[2. (Machida1999Transforming) Junichiro Machida, Koh-ichiro Yoshiura, Carrie D. Funkhauser, Nagato Natsume, Tsuyoshi Kawai, and Jeffrey C. Murray. Transforming growth factor-α (tgfa): genomic structure, boundary sequences, and mutation analysis in nonsyndromic cleft lip/palate and cleft palate only. Genomics, 61(3):237–242, November 1999. URL: http://dx.doi.org/10.1006/GENO.1999.5962, doi:10.1006/geno.1999.5962. This article has 95 citations and is from a peer-reviewed journal.](https://doi.org/10.1006/GENO.1999.5962)

[3. (DefeoJones1988StructureFunction) Deborah Defeo-Jones, Joseph Y. Tai, Ronald J. Wegrzyn, Gerald A. Vuocolo, Audrey E. Baker, Linda S. Payne, Victor M. Garsky, Allen Oliff, and Mark W. Riemen. Structure-function analysis of synthetic and recombinant derivatives of transforming growth factor alpha. Molecular and Cellular Biology, 8(8):2999–3007, August 1988. URL: http://dx.doi.org/10.1128/mcb.8.8.2999-3007.1988, doi:10.1128/mcb.8.8.2999-3007.1988. This article has 3 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.8.8.2999-3007.1988)

[4. (Thomas1992Immunoreactivity) D M Thomas, M M Nasim, W J Gullick, and M R Alison. Immunoreactivity of transforming growth factor alpha in the normal adult gastrointestinal tract. Gut, 33(5):628–631, May 1992. URL: http://dx.doi.org/10.1136/gut.33.5.628, doi:10.1136/gut.33.5.628. This article has 78 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/gut.33.5.628)

[5. (Vieira2006Association) Alexandre R. Vieira. Association between the transforming growth factor alpha gene and nonsyndromic oral clefts: a huge review. American Journal of Epidemiology, 163(9):790–810, February 2006. URL: http://dx.doi.org/10.1093/aje/kwj103, doi:10.1093/aje/kwj103. This article has 61 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/aje/kwj103)

[6. (Mishra2019The) Sonakshi Mishra, Carolina Bernal, Marianna Silvano, Santosh Anand, and Ariel Ruiz i Altaba. The protein secretion modulator tmed9 drives cnih4/tgfα/gli signaling opposing tmed3-wnt-tcf to promote colon cancer metastases. Oncogene, 38(29):5817–5837, June 2019. URL: http://dx.doi.org/10.1038/s41388-019-0845-z, doi:10.1038/s41388-019-0845-z. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-019-0845-z)

[7. (Brachmann1989Transmembrane) Rainer Brachmann, Patricia B. Lindquist, Mariko Nagashima, William Kohr, Terry Lipari, Mary Napier, and Rik Derynck. Transmembrane tgf-α precursors activate egf/tgf-α receptors. Cell, 56(4):691–700, February 1989. URL: http://dx.doi.org/10.1016/0092-8674(89)90591-6, doi:10.1016/0092-8674(89)90591-6. This article has 311 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/0092-8674(89)90591-6)

[8. (Groenen1994StructureFunction) Leo C. Groenen, Edouard C. Nice, and Antony W. Burgess. Structure-function relationships for the egf/tgf-α family of mitogens. Growth Factors, 11(4):235–257, January 1994. URL: http://dx.doi.org/10.3109/08977199409010997, doi:10.3109/08977199409010997. This article has 175 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/08977199409010997)

[9. (Gottlieb1988Detection) A B Gottlieb, C K Chang, D N Posnett, B Fanelli, and J P Tam. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. The Journal of experimental medicine, 167(2):670–675, February 1988. URL: http://dx.doi.org/10.1084/jem.167.2.670, doi:10.1084/jem.167.2.670. This article has 164 citations.](https://doi.org/10.1084/jem.167.2.670)

[10. (Walz1995Transforming) TM Walz, C Malm, BK Nishikawa, and A Wasteson. Transforming growth factor-alpha (tgf-alpha) in human bone marrow: demonstration of tgf-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin. Blood, 85(9):2385–2392, May 1995. URL: http://dx.doi.org/10.1182/blood.v85.9.2385.bloodjournal8592385, doi:10.1182/blood.v85.9.2385.bloodjournal8592385. This article has 14 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood.v85.9.2385.bloodjournal8592385)

[11. (Rullo2007TGF) Rosario Rullo, Fernando Gombos, Franca Ferraraccio, Antonio Farina, Danila Morano, Vincenzo Festa, Daniele Del Viscovo, Annalisa Palmieri, Marcella Martinelli, Luca Scapoli, Furio Pezzetti, and Francesco Carinci. Tgf alpha has low protein expression in nonsyndromic clefts. Journal of Craniofacial Surgery, 18(6):1276–1280, November 2007. URL: http://dx.doi.org/10.1097/scs.0b013e3180de6506, doi:10.1097/scs.0b013e3180de6506. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/scs.0b013e3180de6506)

[12. (Markowitz1990Growth) S D Markowitz, K Molkentin, C Gerbic, J Jackson, T Stellato, and J K Willson. Growth stimulation by coexpression of transforming growth factor-alpha and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. Journal of Clinical Investigation, 86(1):356–362, July 1990. URL: http://dx.doi.org/10.1172/jci114709, doi:10.1172/jci114709. This article has 103 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci114709)

[13. (Derynck1986Transforming) Rik Derynck. Transforming growth factor‐α: structure and biological activities. Journal of Cellular Biochemistry, 32(4):293–304, January 1986. URL: http://dx.doi.org/10.1002/jcb.240320406, doi:10.1002/jcb.240320406. This article has 162 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.240320406)

[14. (Lu2013TGFA) Yongping Lu, Qiang Liu, Wei Xu, Zengjian Li, Miao Jiang, Xuefu Li, Ning Zhao, Wei Liu, Yu Sui, Chao Ma, Wenhua Feng, Weitian Han, and Jianxin Li. Tgfa and irf6 contribute to the risk of nonsyndromic cleft lip with or without cleft palate in northeast china. PLoS ONE, 8(8):e70754, August 2013. URL: http://dx.doi.org/10.1371/journal.pone.0070754, doi:10.1371/journal.pone.0070754. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0070754)

[15. (Prestrelski1992Solution) S J Prestrelski, T Arakawa, C S Wu, K D O’Neal, K R Westcott, and L O Narhi. Solution structure and dynamics of epidermal growth factor and transforming growth factor alpha. Journal of Biological Chemistry, 267(1):319–322, January 1992. URL: http://dx.doi.org/10.1016/s0021-9258(18)48496-7, doi:10.1016/s0021-9258(18)48496-7. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)48496-7)